Guillaume Cartron Selected Research

CD20 Antigens

1/2017	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
1/2011	Interindividual variability of response to rituximab: from biological origins to individualized therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guillaume Cartron Research Topics

Disease

40	Neoplasms (Cancer) 01/2022 - 07/2004
32	Lymphoma (Lymphomas) 03/2022 - 02/2002
27	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 09/2007
17	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 02/2002
14	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2022 - 07/2013
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 10/2014
10	B-Cell Lymphoma (Lymphoma, B Cell) 03/2022 - 05/2012
10	Multiple Myeloma 09/2021 - 11/2011
8	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 08/2013
7	Disease Progression 11/2021 - 09/2007
5	Residual Neoplasm 01/2022 - 11/2012
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 01/2018
4	Infections 01/2021 - 01/2017
4	Neutropenia 10/2018 - 06/2016
3	Rheumatoid Arthritis 01/2022 - 01/2014
3	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 01/2013
3	Hematologic Neoplasms (Hematological Malignancy) 02/2018 - 11/2015
3	Autoimmune Diseases (Autoimmune Disease) 02/2018 - 04/2007
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 09/2014 - 04/2007
2	Cytokine Release Syndrome 03/2022 - 11/2020
2	COVID-19 01/2021 - 01/2020
2	Lymphoid Leukemia 01/2019 - 04/2016
2	Plasmablastic Lymphoma 01/2019 - 01/2016
2	Febrile Neutropenia 03/2018 - 01/2018
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 12/2016 - 01/2013
1	Cytopenia 03/2022
1	Carcinogenesis 01/2022
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2022
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2022
1	Neoplasm Metastasis (Metastasis) 11/2021
1	Large Granular Lymphocytic Leukemia 10/2021
1	Hypoxia (Hypoxemia) 09/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2021
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021
1	Pathologic Complete Response 01/2021

Drug/Important Bio-Agent (IBA)

51	Rituximab (Mabthera)FDA Link 03/2022 - 02/2002
24	obinutuzumabIBA 01/2022 - 05/2012
18	Monoclonal AntibodiesIBA 01/2022 - 04/2007
10	Bendamustine Hydrochloride FDA Link 01/2022 - 01/2013
10	Lenalidomide (CC 5013)FDA Link 01/2022 - 05/2016
6	venetoclaxIBA 01/2022 - 03/2018
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 07/2013
5	Biological ProductsIBA 01/2021 - 03/2005
5	Pharmaceutical PreparationsIBA 06/2016 - 10/2009
4	ibrutinibIBA 03/2022 - 09/2019
4	AntigensIBA 01/2022 - 11/2011
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 07/2013
3	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022 - 01/2016
3	Chimeric Antigen ReceptorsIBA 03/2022 - 11/2020
3	RNA (Ribonucleic Acid)IBA 09/2021 - 01/2017
3	InterferonsIBA 09/2021 - 08/2011
3	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 01/2020
3	fludarabineIBA 01/2021 - 01/2018
3	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 07/2013
3	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 11/2012
3	AntibodiesIBA 01/2013 - 12/2009
2	PlatinumIBA 03/2022 - 01/2021
2	tisagenlecleucelIBA 03/2022 - 07/2021
2	atezolizumabIBA 01/2022 - 01/2022
2	IronIBA 01/2022 - 10/2018
2	Bortezomib (Velcade)FDA Link 11/2021 - 01/2019
2	axicabtagene ciloleucelIBA 07/2021 - 01/2021
2	tirabrutinibIBA 01/2021 - 01/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2012
2	Prednisone (Sone)FDA LinkGeneric 01/2021 - 07/2013
2	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 01/2021
2	daratumumabIBA 12/2020 - 01/2018
2	EnzymesIBA 01/2020 - 04/2009
2	AnthracyclinesIBA 01/2019 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 03/2018 - 01/2013
2	CD20 AntigensIBA 01/2017 - 01/2011
2	Immunoglobulins (Immunoglobulin)IBA 01/2017 - 02/2002
2	Immunoglobulin G (IgG)IBA 01/2013 - 07/2004
2	ofatumumab FDA Link 04/2012 - 01/2010
2	ibritumomab tiuxetan (Zevalin)FDA Link 11/2011 - 01/2010
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2008 - 01/2003
1	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2022
1	SaltsIBA 03/2022
1	ORALIT (ORS)IBA 03/2022
1	Histones (Histone)IBA 01/2022
1	tazemetostatIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Gemcitabine FDA Link 01/2022
1	NivolumabIBA 01/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022
1	BIX 01294IBA 11/2021
1	Histone MethyltransferasesIBA 11/2021
1	ruxolitinibIBA 10/2021
1	Interleukin-6 (Interleukin 6)IBA 09/2021
1	MethyltransferasesIBA 01/2021

Therapy/Procedure

27	Therapeutics 10/2022 - 09/2007
22	Drug Therapy (Chemotherapy) 01/2022 - 04/2007
7	Stem Cell Transplantation 03/2022 - 08/2011
4	Radiotherapy 11/2018 - 06/2005
3	Transplantation 01/2017 - 01/2003
2	Immunotherapy 01/2021 - 01/2018
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 09/2012
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2018 - 01/2003
1	Precision Medicine 09/2021